Adjuvant high‐dose interferon for cutaneous melanoma is most beneficial for patients with early stage III disease
Daniel A. Anaya(Baylor College of Medicine), Janice N. Cormier(Christiana Care Health System), Merrick I. Ross(Johns Hopkins University), Xuelin Huang(The University of Texas MD Anderson Cancer Center), Lei Feng(Ministry of Public Security of the People's Republic of China), Jeffrey E. Gershenwald(The University of Texas MD Anderson Cancer Center), Yan Xing(Peking University), Luis H. Camacho(St. Luke's Episcopal Hospital), Paul F. Mansfield(The University of Texas MD Anderson Cancer Center), Jeffrey E. Lee(The University of Texas MD Anderson Cancer Center)
Cited by 20
Related Papers
Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer
|New England Journal of Medicine|2012|8k
Final Version of 2009 AJCC Melanoma Staging and Classification
|Journal of Clinical Oncology|2009|4.6k
Melanoma staging: Evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual
|CA A Cancer Journal for Clinicians|2017|2.3k
An improvement of the 2ˆ(-delta delta CT) method for quantitative real-time polymerase chain reaction data analysis.
|PubMed|2013|1.6k
Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma
|New England Journal of Medicine|2017|1.4k